Research programme: antibody therapeutics - Duke University/Grid Therapeutics

Drug Profile

Research programme: antibody therapeutics - Duke University/Grid Therapeutics

Alternative Names: GT 103

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Duke University
  • Developer Duke University; Grid Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Complement factor H inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 30 Oct 2017 Grid Therapeutics enters into collaboration with Catalent Pharma Solutions to develop and manufacture GT 103 for treatment of Solid tumours
  • 30 Oct 2017 Grid Therapeutics plans a phase I trial of GT 103 for solid tumours (Late-stage disease) in the first half of 2019
  • 22 Aug 2017 Antibodies related to complement factor H licensed to Grid Therapeutics from Duke University for the treatment of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top